Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats (Q46881133)

26 December 2017

title

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats (English)

1 reference

26 December 2017

author name string

Nagano N

1

1 reference

26 December 2017

Miyata S

2

1 reference

26 December 2017

Abe M

3

1 reference

26 December 2017

Kobayashi N

4

1 reference

26 December 2017

Wakita S

5

1 reference

26 December 2017

Yamashita T

6

1 reference

26 December 2017

Wada M

7

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

26 December 2017

published in

Kidney International

1 reference

26 December 2017

volume

69

1 reference

26 December 2017

page(s)

531-537

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000020

exact match

0 references

cites work

Direct effect of phosphate on parathyroid function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Mechanisms of secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

The phosphatonin pathway: new insights in phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

FGF-23 in patients with end-stage renal disease on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Renal mineral handling in normal rats treated with sevelamer hydrochloride (Renagel), a noncalcemic phosphate binder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Animal model of adenine-induced chronic renal failure in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Effect of phosphate on parathyroid hormone secretion in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000020

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000020

1 reference

26 December 2017

PubMed ID

16395276

1 reference

26 December 2017